RE: 25,000 buyer7 May 2020 13:21
It noted that using Paraytec's imaging capability in partnership with aptamers from Aptamer Group which bind to the spike protein on the virus, the objective is to develop a portable test, which can generate a result in a matter of minutes from a swab provided at the test location and require no specialist skills to be operated.
With regards to Kirkstall Limited, in which it has an 80% holding, Braveheart noted that Kirkstall's Quasi-Vivo systems are being considered by Aptamer Group to provide a possible test bed for testing of aptamer-based cancer therapeutics which they are developing.
And with regards to Sentinel Medical Limited, in which it has a 38.38% holding, Braveheart said that, as previously reported, Sentinel has a licence to use Paraytec's imaging technology to detect bladder cancer and has ongoing trials with bladder cancer patient samples, to develop a point-of-care instrument.
It said Sentinel has submitted a grant application with University of Sheffield, Aptamer Group and the Leeds Teaching Hospitals NHS Trust, to enhance this product using aptamers.